IRWD Share Price

Open 19.04 Change Price %
High 19.20 1 Day -0.45 -2.36
Low 18.54 1 Week 0.62 3.44
Close 18.62 1 Month 2.30 14.09
Volume 997106 1 Year 6.24 50.40
52 Week High 19.39
52 Week Low 12.02
IRWD Important Levels
Resistance 2 19.23
Resistance 1 18.98
Pivot 18.79
Support 1 18.26
Support 2 18.01
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ASTI 0.00 0.00%
SIRI 5.29 3.32%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
NIHD 0.74 39.62%
NIHD 0.74 39.62%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEZS 1.18 22.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
CLSN 0.23 -93.11%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)

IRWD Technical Analysis 5
As on 26th May 2017 IRWD Share Price closed @ 18.62 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 15.34 & Strong Buy for SHORT-TERM with Stoploss of 16.96 we also expect STOCK to react on Following IMPORTANT LEVELS.
IRWD Target for May
1st Target up-side 17.33
2nd Target up-side 18.03
3rd Target up-side 18.74
1st Target down-side 15.31
2nd Target down-side 14.61
3rd Target down-side 13.9
IRWD Other Details
Segment EQ
Market Capital 1211006720.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ironwoodpharma.com
IRWD Address
IRWD
301 Binney Street
Cambridge, MA 02142
United States
Phone: 617-621-7722
Fax: 617-494-0480
IRWD Latest News
Interactive Technical Analysis Chart Ironwood Pharmaceuticals, Inc. ( IRWD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Ironwood Pharmaceuticals, Inc.
IRWD Business Profile
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines. The Company is engaged in the area of guanylate cyclase type-C (GC-C), agonists and in the science and treatment of gastrointestinal diseases. Its two GC-C agonists are linaclotide and IW-9179.